The Vastkind Briefing

Success! Now Check Your Email

To complete Subscribe, click the confirmation link in your inbox. If it doesn’t arrive within 3 minutes, check your spam folder.

Follow Us

Longevity

Longevity science, aging biology, clinical evidence, biotech claims, and the real limits of the anti-aging frontier.

Split biotech illustration showing a controlled cell-regeneration pathway beside a more chaotic reprogramming pathway, symbolizing OSK versus OSKM tradeoffs.
Longevity Longevity

Partial Reprogramming OSK vs OSKM: Why “Partial” Is the Whole Trick

The future of reprogramming depends less on ambition than on control.

Vastkind Profile image
by Vastkind